BASAGLAR KWIK PEN (Insulin Glargine (100IU/ml))

Basaglar Kwikpen Solution for Injection is a prolonged-action insulin treatment intended for managing type 1 and type 2 diabetes in both adults and pediatric patients. This medication maintains a consistent insulin level in the bloodstream throughout the day, which aids in regulating blood glucose concentrations. By effectively stabilizing these levels, Basaglar can help mitigate potential diabetes-related complications.
This insulin formulation may be utilized on its own or alongside rapid-acting insulins or other antidiabetic medications, as prescribed by a healthcare professional. It is crucial for patients to receive proper instruction on the subcutaneous injection technique from a healthcare provider. Adhering to the prescribed dosing schedule is vital for achieving optimal therapeutic outcomes. Discontinuation of the medication may lead to dangerously elevated blood sugar levels, increasing the risk of severe complications. Basaglar is part of a comprehensive diabetes management regimen, which should also encompass a balanced diet, regular physical activity, and weight management, as advised by a healthcare professional.
A notable side effect of Basaglar is the risk of hypoglycemia, which underscores the importance of using the correct dosage, maintaining regular meal patterns, and frequently checking blood glucose levels. Additionally, excessive alcohol consumption may further lower blood sugar levels. Other frequently reported adverse effects include swelling in the extremities, skin reactions at the injection site, allergic responses, itching, rashes, changes in fat distribution at the injection area, and possible weight gain.